Priming of anti-cancer cytotoxic CD8+ T cell depends largely on the proficient (neo-)antigen cross-presentation (XP) and cross-dressing capabilities of type 1 conventional dendritic cells (cDC1s)1–3. Here, CD8A is linked to cancer.